Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1907685-81-7
Molecular formula
C10H15N2O7P
Molecular weight
306.21 g/mol
Drug class
Carbidopa prodrugpyridoxine-independent peripheral dopa-decarboxylase inhibitor component of VYALEV
Mechanism of action
Foscarbidopa is a phosphate prodrug converted to carbidopa, which inhibits peripheral aromatic L-amino-acid decarboxylase and reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the brain. It is used as part of the fixed foscarbidopa/foslevodopa combination.
Indications / reported uses
Component of the fixed combination VYALEV (foscarbidopa/foslevodopa) for treatment of motor fluctuations in adults with advanced Parkinson disease; not a stand-alone approved indication
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Foscarbidopa Environmental Risk Assessment (ERA) (the Foscarbidopa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.